Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Bullboard Posts
Comment by oxinoson Oct 08, 2020 9:17am
153 Views
Post# 31685620

RE:FDA Will No Longer Review EUA Submissions for SARS-CoV-2 Lab

RE:FDA Will No Longer Review EUA Submissions for SARS-CoV-2 Lab
Watcher2020 wrote: FDA Will No Longer Review EUA Submissions for SARS-CoV-2 Lab-Developed Tests

Oct 07, 2020 | Madeleine Johnson NEW YORK – The US Food and Drug Administration announced on Wednesday it will no longer review SARS-CoV-2 Emergency Use Authorization submissions for lab-developed tests.

We are currently in a different phase of the pandemic with respect to tests than we were previously," he said, noting that the FDA has authorized more than 250 tests to be run in labs, and more than 400 are offered under the agency's notification pathway.

FDA continues to prioritize review of EUA requests for point-of-care tests, home collection tests, at-home tests, tests that reduce reliance on certain types of test supplies, and high-throughput, widely distributed tests, Stenzel asserted.


Now that FDA has made such a decision and Health Canada seems to follow the lead of FDA it would be time for HC to adopt the same and lighten their load of the 94 applications that they are in the reviewing. The few that would remain would not take long to finally approve. Sona Nanotech lateral flow antigen test should be front and center.  Go HC, you can do it!
Bullboard Posts